Brainstorm Cell Therapeutics reported $13.25M in Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Adamis Pharmaceuticals ADMP:US USD 12.14M 5.56M
Biogen BIIB:US USD 24.85B 227.2M
Brainstorm Cell Therapeutics BCLI:US USD 13.25M 5.71M
Cytokinetics CYTK:US USD 1.08B 304.24M
Gilead Sciences GILD:US USD 62.56B 313M
Halozyme Therapeutics HALO:US USD 1.86B 83.15M
Idera Pharmaceuticals IDRA:US USD 103.68M 77.38M